Last reviewed · How we verify

piflufolastat (18F) — Competitive Intelligence Brief

piflufolastat (18F) (piflufolastat (18F)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PSMA-targeting PET imaging agent. Area: Oncology.

marketed PSMA-targeting PET imaging agent PSMA (prostate-specific membrane antigen) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

piflufolastat (18F) (piflufolastat (18F)) — Blue Earth Diagnostics. Piflufolastat (18F) is a fluorine-18 labeled small molecule that binds to prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of PSMA-expressing tumors.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
piflufolastat (18F) TARGET piflufolastat (18F) Blue Earth Diagnostics marketed PSMA-targeting PET imaging agent PSMA (prostate-specific membrane antigen)
F-18-PSMA-1007 F-18-PSMA-1007 ABX advanced biochemical compounds GmbH phase 3 Radiopharmaceutical; PSMA-targeting PET imaging agent PSMA (prostate-specific membrane antigen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PSMA-targeting PET imaging agent class)

  1. Blue Earth Diagnostics · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). piflufolastat (18F) — Competitive Intelligence Brief. https://druglandscape.com/ci/piflufolastat-18f. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: